miR-429与肿瘤

miR-429是miR-200家族成员之一。研究表明，miR-429异常表达与肿瘤的发生、发展、转移、凋亡和耐药等密切相关。但miR-429在肿瘤中所起的作用一直有争议，可作为肿瘤抑制剂或促进剂，具肿瘤细胞/组织特异性。其在骨肉瘤、肾癌、卵巢癌、乳腺癌、宫颈癌、胶质瘤、口腔鳞状细胞癌、胃癌、食管癌、胰腺癌中起抑癌作用，而在肺癌、前列腺癌和子宫内膜癌中起促癌作用，但在结肠癌、肝癌、膀胱癌中的作用尚不明确。本文综述了近年来miR-429在肿瘤发生、发展中的作用及潜在的调控机制，为其作为肿瘤诊断、治疗及预后的潜在生物标记分子提供新的启示和参考。

miR-429 and Cancer

miR-429 is a member of miR-200 family. Accumulated evidence has indicated that miR-429 dysregulation is associated with the development, progression, metastasis, apoptosis and drug resistance of cancers. However, the roles of miR-429 in cancers are still controversial because it might specifically function either as a tumor suppressor or promoter candidate for certain cancers depending on the particular types of tumor cells/tissues. miR-429 appears to have a tumor-suppressive role in osteosarcoma, renal cell carcinoma, ovarian cancer, breast cancer, cervical cancer, glioblastoma, oral squamous cell carcinoma, gastric carcinoma, esophageal cancer and pancreatic cancer. However, miR-429 specifically promotes tumorigenesis of lung cancer, prostate cancer and endometrial cancer. While miR-429 shows paradoxical roles in colorectal cancer, hepatocellular carcinoma and bladder cancer. This article summarizes the potential roles of miR-429 and its mechanisms in tumorigenesis, indicating that miR-429 might be potentially used as a biomarker for the diagnosis, treatment and prognosis of certain cancers in the future.